GANX catalysts
Catalysts and events linked to GANX, newest first.
GANX stock catalysts and risks
Latest published review: 2026-10-20
| Development | Transmission channel | Evidence | Condition to watch |
|---|---|---|---|
| Gain Therapeutics to Present GT-02287 Parkinson Data at Seoul Congress 2026-09-30 · Up | biotech clinical catalyst positioning ahead of medical congress presentation | Gain Therapeutics announced poster presentation of GT-02287 long-term open-label data for Oct 7, 2026. | Not recorded |
| Gain Therapeutics Schedules Parkinson's Data Presentation 2026-09-30 · Up | clinical pipeline milestone and trial efficacy readout | Poster presentation of long-term open-label data on GT-02287 scheduled for October 7, 2026. | Not recorded |
Do these developments change your position?
Review GANX alongside your other holdings and identify which decision deserves attention first.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
DateCardAvg 5d
- 2026-09-30Gain Therapeutics to Present GT-02287 Parkinson Data at Seoul CongressGANX
- 2026-09-30Gain Therapeutics Schedules Parkinson's Data PresentationGANX
- 2026-09-30Gain Therapeutics Schedules Parkinson's Data PresentationGANX
- 2026-09-30Gain Therapeutics to Present GT-02287 Parkinson Data at Seoul CongressGANX
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.